Lp(a): the inherited heart risk a routine cholesterol test can miss
About this article: AI-assisted, not independently clinically reviewed
Prepared with AI-assisted research using the sources below. Not independently reviewed by a clinician. Guidance and individual circumstances can change; use this article to prepare for a clinical conversation, not to choose treatment.
Sources checked 2026-09-05. Last updated 2026-09-05.
The short version
- Lp(a) is largely inherited and needs a separate blood test.
- Keep the laboratory's original unit; do not use a fixed conversion.
- A high result changes a risk conversation, not a diagnosis of an imminent heart attack.
A cholesterol report can look reassuring and still leave an important question unanswered: was lipoprotein(a), usually written Lp(a), measured? It is a separate marker, not another name for LDL cholesterol. Learning about it is particularly useful when heart disease seems to run through a family despite apparently healthy habits.
What the test measures
Lp(a) is a cholesterol-carrying particle with an additional protein attached. Its concentration is largely determined by inheritance. The European Atherosclerosis Society's 2022 consensus describes evidence linking higher levels causally to atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Risk increases along a spectrum: a result is not a switch that changes someone from completely safe to inevitably unwell.
Evidence: Kronenberg et al., European Heart Journal 2022: EAS Lp(a) consensus
The March 2026 US multisociety dyslipidemia guideline recommends measuring Lp(a) at least once in a lifetime. That is an invitation to discuss testing, not a claim that every person needs frequent repeat measurements. Your clinician can explain whether a previous result, a relevant illness or a particular treatment makes a repeat useful.
Evidence: AHA/ACC: 2026 dyslipidemia guideline
Read the number and the unit together
Laboratories commonly report Lp(a) in nmol/L, a measure related to particle concentration, or mg/dL, a mass concentration. The particles differ in size, so multiplying by one fixed factor can give a misleading answer. Preserve the original value, unit, laboratory and reference information. When comparing reports, check that they actually use the same measurement system.
Evidence: EAS authors, Atherosclerosis 2023: Lp(a) consensus questions and answers
The American Heart Association identifies 125 nmol/L or 50 mg/dL as commonly used high-risk thresholds. These are separately expressed clinical cutoffs, not a precise conversion formula. The importance of a result also depends on age, existing disease, LDL-C, blood pressure, smoking, diabetes and family history. An isolated flag on a report cannot calculate all of that for you.
Evidence: American Heart Association: Lipoprotein(a) · Kronenberg et al., European Heart Journal 2022: EAS Lp(a) consensus
What can change after a high result?
Lifestyle usually changes Lp(a) much less than it changes some other risk factors. That does not make healthy habits pointless, and a high value is not evidence that you have failed at them. The useful discussion is about reducing the risks that are modifiable and whether close relatives should be offered testing. Do not start aspirin, stop cholesterol medicine or buy a supplement simply to respond to this one number.
Evidence: American Heart Association: Lipoprotein(a) · Kronenberg et al., European Heart Journal 2022: EAS Lp(a) consensus
A lower laboratory value is not the same as fewer heart attacks
A 2022 phase 2 trial studied olpasiran in 281 people who already had atherosclerotic cardiovascular disease and elevated Lp(a). It produced large reductions in the marker. However, its primary outcome was the change in Lp(a) at 36 weeks, not prevention of heart attacks or strokes. This distinction matters whenever a headline says a new treatment 'cuts risk' by quoting a biomarker reduction. This article does not establish current approval, availability in Qatar or proven event prevention for an Lp(a)-specific medicine.
Evidence: O'Donoghue et al., NEJM 2022: phase 2 olpasiran trial
Bring a small, useful record
- Save the original report, including the test name, value, unit and date. Check any scanned copy against the original before using it.
- Write down which relatives had heart attacks, strokes or aortic valve disease and, if known, their ages at diagnosis. Mark uncertain details as uncertain.
- Bring your current medication list and recent standard cholesterol results, so the discussion is about your whole situation.
- Ask: Does this result change my prevention plan? Would testing a parent, sibling or child be useful? When, if ever, should I repeat it?
Evidence: American Heart Association: Lipoprotein(a) · Kronenberg et al., European Heart Journal 2022: EAS Lp(a) consensus
The best outcome of testing is a clearer plan, not a more alarming dashboard. Keep the result available for future appointments, record the agreed next step, and avoid repeatedly interpreting the same value without new clinical context.
This article is educational and is not medical advice, a diagnosis, or a treatment recommendation. CardioTrack is not intended for diagnosis or treatment. Always discuss your own results with a qualified clinician.